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Objective: Comorbidity between anxiety and cannabis use is common yet the nature of
the association between these conditions is not clear. Four theories were assessed, and
a fifth hypothesis tested to determine if the misattribution of stress symptomology plays
a role in the association between state-anxiety and cannabis.
Methods:Three-hundred-sixteen participants ranging in age from 18 to 71 years completed
a short online questionnaire asking about their history of cannabis use and symptoms of
stress and anxiety.
Results: Past and current cannabis users reported higher incidence of lifetime anxiety than
participants who had never used cannabis; however, these groups did not differ in state-
anxiety, stress, or age of onset of anxiety. State-anxiety and stress were not associated
with frequency of cannabis use, but reported use to self-medicate for anxiety was positively
associated with all three. Path analyses indicated two different associations between anx-
iety and cannabis use, pre-existing and high state-anxiety was associated with (i) higher
average levels of intoxication and, in turn, acute anxiety responses to cannabis use; (ii)
frequency of cannabis use via the mediating effects of stress and self-medication.
Conclusion: None of the theories was fully supported by the findings. However, as
cannabis users reporting self-medication for anxiety were found to be self-medicating
stress symptomology, there was some support for the stress-misattribution hypothesis.
With reported self-medication for anxiety being the strongest predictor of frequency of use,
it is suggested that researchers, clinicians, and cannabis users pay greater attention to the
overlap between stress and anxiety symptomology and the possible misinterpretation of
these related but distinct conditions.
Keywords: cannabis, anxiety, stress, self-medication, path analysis
Globally, cannabis is the most commonly used illicit drug (1)
and anxiety is the most prevalent mental disorder (2). Large
cross-sectional population-based surveys, such as the Australian
National Survey of Mental Health and Wellbeing, the United States
National Comorbidity Survey, and National Epidemiological Survey
of Alcohol and Related Conditions, consistently find that cannabis
users report a higher incidence of anxiety disorders and symp-
toms than non-cannabis users [e.g., Ref. (3–5)]. Australian data,
for example, indicates a 40.5% prevalence rate for anxiety disorders
in current cannabis users with a 12-month cannabis use disorders
(CUD) and a rate of 20.8% for current users without CUD, in
comparison to 11.2% for non-users (5). As such, the existence of
comorbidity between anxiety and cannabis use is well known.
Similarly, well known is that the subjective effects of acute
cannabis intoxication, which typically include feelings of eupho-
ria and relaxation, also include feelings of anxiety and/or paranoia
for a significant proportion of users (6, 7). Thus, many people
report using cannabis to relieve symptoms of stress and/or anxiety,
while concurrently some users report experiencing acute anxiety
symptoms when intoxicated (8). Inconsistent with both of these
types of user experiences, Tournier et al. (9) found no evidence
for the anxiolytic (i.e., anxiety-reducing) or anxiogenic (i.e., anx-
iety inducing or increasing) effects of cannabis use in daily life
when using an experience sampling method. Tournier et al. (9)
also failed to find a significant association between state-anxiety
and cannabis use, but found that use was associated with agora-
phobia. Cannabis use has also been found to be related to panic
disorder [e.g., Ref. (10, 11)], social phobia [e.g., Ref. (10)], and
posttraumatic stress disorder [e.g., Ref. (12)], yet other studies
have reported that cannabis use disorder is unrelated to anxiety
disorders other than social anxiety disorder [e.g., Ref. (13)], or that
associations between cannabis use and anxiety are non-significant
after controlling for confounders [e.g., Ref. (14)].
These apparent contradictions suggest that there is a need to
more clearly distinguish between the different types of anxiety (i.e.,
state-anxiety, drug-induced anxiety) that occur in the context of
cannabis use. There is also clearly a need to clarify how cannabis
use is related to the development and perpetuation of anxiety
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and/or how anxiety contributes to the use of cannabis. Further-
more, it is important to investigate whether the common tendency
for lay people to use the words “anxiety” and “stress” interchange-
ably, which stems from a lack of awareness of the distinguishing
features of each (15) has contributed to the mixed results evident
in the literature investigating cannabis use and anxiety.
THE RELATIONSHIP BETWEEN CANNABIS AND ANXIETY
Four main theories have been proposed to explain the relation-
ship between cannabis use and anxiety (16), each of which has
supporting evidence. The common factor theory proposes that the
associations found between cannabis and anxiety exist because
both have common antecedents, which may include biological,
social, and environmental factors such as childhood trauma, per-
sonality, and socioeconomic adversity (16–18). This theory is
supported, for example, by the findings from two longitudinal
studies, the Netherlands Mental Health Survey and Incidence Study
(19) and the Christchurch Health and Development Study [e.g., Ref.
(20)], where associations between cannabis use and anxiety were
non-significant after potential confounding factors were taken into
account.
The self-medication hypothesis proposes the association exists
because individuals experiencing anxiety are motivated to use
cannabis to alleviate their negative affective symptoms (16, 18, 21).
This theory is concordant with prior study results indicating that
stress relief, relaxation, and anxiety/tension reduction are the most
common reasons for cannabis use (22, 23), and that cannabis can
induce anxiolytic effects (24). Further supporting evidence comes
from past findings that a large proportion of individuals with
comorbid anxiety and CUD experience the onset of their anxiety
disorder prior to the onset of cannabis use (3). Moreover, Buckner
and Carroll’s (25) finding that reductions in anxiety symptomol-
ogy within a cannabis-dependent sample led to reduced cannabis
use, but that reductions in cannabis use did not lead to decreased
levels of anxiety, also support the self-medication hypothesis.
The third theory posits a direct causal association between
cannabis use and anxiety, whereby the use of cannabis increases
the risk of the subsequent development of an anxiety disorder (16,
18). This hypothesis is consistent with clinical observations that
panic symptoms can occur during or immediately after cannabis
use (26, 27), suggesting that the drug might also directly contribute
to, or at least augment, anxiety symptoms (18, 28). It is also sup-
ported by findings from longitudinal studies, such as the Victorian
Adolescent Health Cohort Study [e.g., Ref. (17, 18)], where frequent
cannabis use during adolescence has been found to be associated
with greater risk for subsequent anxiety disorders during ado-
lescence and early adulthood, even after potential confounding
factors were controlled statistically.
The final, somewhat unifying, theory suggests that the asso-
ciations between cannabis use and anxiety can be explained by
a reciprocal feedback loop, with simultaneous causation between
cannabis use and anxiety arising from common factors, and where
each condition leads to the exacerbation of the other through direct
causality and/or self-medication (16). This theory is supported
in part by the findings from Van Dam et al.’s (29) investigation
of differences between clinically anxious and non-anxious heavy
cannabis users (daily/near daily use for 12 months or longer).
Anxious users consumed more cannabis (in grams) per week,
reported more cannabis use-related problems, and had higher
levels of depression and schizotypal symptomology than non-
anxious users, yet the groups were matched demographically and
did not differ in relation to age at onset of cannabis use, average
high, or duration of use. The authors noted that these findings
suggest anxiety that may be causally related to the development of
abuse/dependence for heavy users of cannabis. This proposition
is somewhat supported by findings from the longitudinal CanDep
study, which followed frequent cannabis users (used>3 times per
week for at least 12 months) over 3 years (10, 30).
Cross-sectional analysis of the baseline CanDep data compar-
ing non-users to dependent and non-dependent users found that
dependent users were more likely to experience anxiety disorders
than non-dependent users and non-users, with these two latter
groups reporting comparable levels of anxiety (10). Similar to Van
Dam et al. (29), van der Pol et al. (10) found that the two cannabis
user groups did not differ in relation to key cannabis use factors,
including age of first use and onset of regular use, duration, and
frequency of use. However, in contrast to Van Dam et al. (29), van
der Pol et al. (10) found that dependent and non-dependent users
also did not differ in relation to the quantity of cannabis used
(number of joints per day, dose). Nevertheless, dependent users
were more likely than non-dependent users to use cannabis alone,
use for coping and expansion motives, to be experiencing a mood
disorder, and to report other current substance use (10).
As such, these two cross-sectional studies (10, 29) suggest that
there is a subgroup of frequent cannabis users that is more prone to
experience cannabis dependence and anxiety (as well as other psy-
chopathology) than other users with similar exposure to cannabis
use. These studies do not tend to shed light on the direction
and/or existence of any causal relationships between cannabis
use and anxiety. This issue is, however, addressed by longitudi-
nal findings from the CanDep study (30), where non-dependent
frequent users were followed from baseline for 3 years to inves-
tigate the development of cannabis dependence. In this study,
anxiety was not found to be predictive of dependence, nor was
dependence predicted by cannabis exposure (e.g., age at onset,
frequency, quantity, dose, etc.) or any of the many stable factors
that are commonly considered to be risk factors for dependence
(e.g., childhood adversity, demographics, etc.) that were assessed
in the study. Rather, cannabis dependence was predicted by living
alone, coping motives for use, and stress (measured as number of
negative recent life events).
STRESS, ANXIETY AND CANNABIS USE
Other than van der Pol et al.’s (30) study, no prior studies appear
to have investigated the distinction between stress and anxiety in
cannabis users. Anxiety and stress are overlapping but quite dis-
tinct states. For example, the stress subscale of the Depression Anx-
iety Stress Scales (DASS) asks respondents about tension, persis-
tent arousal symptoms, irritability, and difficulty relaxing, whereas
the anxiety subscale asks about symptoms of arousal/tension and
fear-related symptoms and cognitions (31). Hence, while auto-
nomic arousal is a core feature of both states, suggesting that there
may be a natural continuity or overlap between the two syndromes,
there are salient differences between the disorders, such that fear
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cognitions occur in anxiety but not in high stress conditions. In the
past, researchers have experienced substantial difficulties in sepa-
rating the two constructs (31), so it is likely that cannabis users may
also not appreciate the salient differences between the two states.
Accordingly, we advance a fifth explanation for the associations
seen between anxiety and cannabis use, the stress-misattribution
hypothesis, which suggests that some proportion of the associ-
ations evident between anxiety and cannabis are due to users
misattributing their stress symptomology, believing that they are
actually symptoms of anxiety. This hypothesis fits within the self-
medication hypothesis, such that users reporting self-medication
to relieve anxiety symptomology are expected to in fact be self-
medicating stress/tension rather than (or in addition to) anxiety
symptoms. Additionally, it is posited that this hypothesis is in keep-
ing with the reciprocal feedback loop hypothesis, with stress play-
ing a central role, along with anxiety, in the escalation of cannabis
use and, in turn, also being exacerbated by increased cannabis use.
Consistent with this hypothesis, there is evidence in the litera-
ture to suggest that cannabis users are exposed to more stressors
than non-users, and dependent users to more again than non-
dependent users. In a review of the literature investigating stress as
a risk factor for cannabis use/misuse, Hyman and Sinha (32) iden-
tified family dysfunction, social disadvantage, and maltreatment
(i.e., physical, emotional and sexual abuse, and neglect) during
childhood as stressful conditions commonly found to be associ-
ated with both early onset of cannabis use and later dependence,
while trauma occurring during adulthood (e.g., interpersonal
violence, combat trauma) and chronic stress were similarly impli-
cated in the development of cannabis dependence. These types
of traumatic life/events and life stressors are typically reported
more often by cannabis users than non-users, and by depen-
dent users than non-dependent users [e.g., Ref. (10, 20, 33)]. The
model put forward by Hyman and Sinha (32) links these stress-
inducing life events/circumstances to altered stress responses and
coping deficits/disruptions and then the consumption of cannabis
for coping motives and an associated increased frequency of
cannabis use. These changes are posited to cause neuroadapta-
tions in the stress and reward circuits (e.g., via cannabis-related
activation of the hypothalamic-pituitary-adrenal [HPA] axis and
increased dopamine release), with an exacerbating cycle then
eventuating, whereby chronic cannabis use is associated with mal-
adaptive coping and poor life decisions, which lead to increased
stressors/stress/distress and, thus, increased cannabis use for cop-
ing/relief. As such, this cycle of exacerbation is consistent with the
reciprocal feedback loop theory.
It is possible that maladaptive coping and/or poor decision-
making in everyday life may be associated with a range of other
differences commonly seen between cannabis users and non-users.
For example, cannabis users are more likely than non-users to
be unemployed/welfare dependent and single/living alone, and
more likely to report lower levels of education, income, and
life and relationship satisfaction [e.g., Ref. (10, 14, 30, 34)],
with these life circumstances often associated with, or indica-
tive of, higher levels of stress/stressors in everyday life. Further
to this, the diagnostic distinctions drawn between cannabis use
and cannabis abuse/dependence (DSM-IV) or cannabis use disor-
der (DSM-5) reflect, at least in part, an escalation of stressors in
an individual’s life. For example, an individual experiencing use-
related social/interpersonal problems (i.e., interpersonal stress)
as well as physical or psychological use-related problems (e.g.,
health-related stressors) meets DSM-5 criteria for cannabis use
disorder (35). Thus, by definition alone, dependent users may be
experiencing higher levels of stress in their everyday lives than
non-dependent users.
Furthermore, the rapidly growing body of research investigat-
ing the endocannabinoid system and, specifically, its inhibitory
role in the modulation of neuronal and behavioral stress responses
[e.g., Ref. (36–38)], also provides support for the existence of
stress-related differences between cannabis users and non-users.
Essentially, the psychoactive effects resulting from cannabis inges-
tion are caused by the binding of exogenous cannabinoids (e.g.,
THC, CBD) to cannabinoid receptors (CB1, CB2) within the endo-
cannabinoid system. In part, this impedes the ability of endoge-
nous cannabinoids (i.e., 2-AG, AEA) to bind with these receptors,
disrupting the usual functioning of the endocannabinoid sys-
tem. The endocannabinoid system is central to the regulation of
emotion and acute and chronic stress responses, also acting to con-
strain basal activation of the HPA axis (39). Consistent with this,
cannabis ingestion has been found to activate the HPA axis, par-
ticularly when used in high doses, with recent research suggesting
that frequent cannabis use may result in persistent hyperactivity
of the HPA axis (38). Thus, increased endocannabinoid signaling
is associated with reductions in stress and anxiety symptomology
and, conversely, disruption of signaling is associated with stress,
anxiety, and depression (40).
To summarize, epidemiological data indicate that cannabis
users report greater exposure to historical stressors (e.g., child-
hood maltreatment) and stressful circumstances in everyday life
(e.g., unemployment/welfare dependence) than never/non-users,
and dependent users report higher levels of these stressors as well as
cannabis use-related stressors than non-dependent users. Frequent
cannabis use may alter the functioning of the endocannabinoid
system, affecting the modulation of HPA axis stress responses, and,
thereby, increasing cannabis users’ vulnerability to stress and anxi-
ety. Further, it is possible that cannabis users who are experiencing
stress but not anxiety, or stress and anxiety, may misattribute at
least some of their stress symptoms to anxiety. As such, individu-
als reporting the use of cannabis for the self-medication of anxiety
symptoms may actually be (at least in part) medicating symptoms
of stress/tension rather than symptoms of anxiety. This would be
consistent with findings that more cannabis users report using the
drug to reduce stress/tension than to reduce their anxiety (22, 23).
THE CURRENT STUDY
Each of the four theories outlined above should predict a different
pattern of results in relation to the association between anxiety and
cannabis use. The common factors theory suggests that cannabis
use is inconsequential to the development of anxiety, whereas
the self-medication, direct causation, and reciprocal feedback loop
theories suggest differing roles for cannabis use in the devel-
opment and management of anxiety symptoms. The proposed
stress-misattribution hypothesis suggests that misidentification of
stress symptomology may account for at least part of the associa-
tion commonly reported between cannabis use and anxiety. Thus,
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FIGURE 1 | Proposed models with reciprocal feedback loop between anxiety and cannabis use variables: (1) without stress; (2) including stress.
in this study, we examined the relationship between stress, anxiety,
and cannabis use to test the ability of these different theories to
explain the commonly reported association between cannabis use
and anxiety.
Accordingly, it was hypothesized that:
1) if cannabis use and anxiety are associated solely because of
common underlying factors:
a) current and past users will be more likely to report lifetime
anxiety than participants who have never used cannabis,
with prevalence for current and past users being similar
and
b) current and past users will not differ in relation to state-
anxiety, but will report higher levels than participants who
have never used cannabis,
2) if the anxiety experienced by cannabis users is caused by their
cannabis use:
a) current users will have higher levels of state-anxiety than
both past users and participants who have never used
cannabis and
b) an exposure/dose–response relationship will be evident,
with levels of state-anxiety reported by current users pre-
dicted by acute anxiety reactions and/or cannabis use fac-
tors (i.e., frequency, potency, intoxication), after controlling
for potential confounding variables,
3) if anxious people use cannabis to self-medicate their symptoms
of anxiety:
a) frequency of self-reported use of cannabis for self-
medication purposes by current users will be predicted by
state-anxiety, after controlling for potential confounding
variables and
b) the frequency of cannabis use reported by current users will
be predicted by state-anxiety and frequency of reported
use for self-medication, after controlling for potential
confounding variables,
4) if the association between anxiety and cannabis use involves a
reciprocal feedback loop path analysis will indicate good fit for a
model with cannabis use for self-medication of anxiety central
to the reciprocal associations between anxiety-related variables
(i.e., state-anxiety, acute anxiety reactions) and cannabis use
variables (i.e., frequency of use, potency, intoxication), as per
Model 1 in Figure 1, and
5) if the stress-misattribution hypothesis posited above is rele-
vant:
a) current cannabis users will report higher levels of stress
symptomology than both past users and participants who
have never used cannabis, with the latter two groups also
differing,
b) levels stress symptomology reported by current users will
be more strongly predictive of both self-medication and fre-
quency of use than state-anxiety in relation to hypotheses
3a and 3b, and
c) the best fit path analysis model will indicate stress symp-
tomology, which is an integral aspect of the associations
between anxiety and cannabis use variables, as per Model 2
in Figure 1.
METHOD
PARTICIPANTS
Participants were primarily recruited via advertisements placed on
online forums and message boards relevant to cannabis use (e.g.,
www.cannabisculture.com) or anxiety and panic disorder (e.g.,
www.panicsurvivor.com). In addition, some participants were
recruited through the University of New England’s (Australia)
Research Participation Opportunities program, which enables
first-year psychology students to receive course credit for partici-
pation in a range of available studies. The single inclusion criterion
was being aged 18 years or older.
The anonymous online questionnaire was completed by
321 participants (52.0% male) aged between 18 and 71 years
(M = 32.3 years; SD= 11.92). Most respondents were employed
(61.7%) or university students (25.9%), with small proportions
being either unemployed (8.9%) or retired (3.5%). The vast major-
ity of participants (86.0%, N= 267) reported using cannabis at
least once in their life, with 53.9% (N= 173) using it during past
12 months. In relation to other substance use, 43% drank alcohol
at least weekly, 37.8% were current tobacco smokers, and 12.1%
had used another illicit drug at least once in their lifetime.
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One-fifth of the current cannabis users reported using it on a
daily basis (21%), while 45% used weekly, 11% monthly, and 23%
used less frequently. Cannabis using participants most commonly
consumed it by smoking a joint (36.6%), with fewer typically using
a bong/waterpipe (16.8%), and 31.6% reporting both methods.
The most common preparation type consumed was heads/buds
(64.0%), with the use of leaf (10.6%) and hash/resin (3.0%) being
less common; 22.4% of cannabis users reported using a range of
preparation types.
MATERIALS
The questionnaire collected demographic data (i.e., age, gender,
employment status) and contained a range of items designed to
assess various aspects of cannabis use and mental health. Qualtrics
Online Survey Software was used for the questionnaire.
Participants were asked if they had ever tried cannabis and, if
so, their age at first use. Those who had used cannabis were also
asked to report whether or not they had used cannabis in the
past 12 months. These questions were used to categorize partic-
ipants into three cannabis use groups: never used, past use, and
current use.
Current cannabis users were asked a number of additional
questions about their use of cannabis in the previous 12 months.
Frequency of use was assessed on a 9-point scale (1=“only once
or twice” to 9=“every day”). Average potency of cannabis con-
sumed was assessed by asking participants how often (0=“never”
to 4=“every time”) they used cannabis with six different lev-
els of potency (1=“very weak” to 6=“extremely strong”). Scores
could range from 4 (“very weak” * “every time”) to 24 (“extremely
strong” * “every time”). Similarly, average level of intoxication
was calculated by asking participants how often (0=“never” to
4=“every time”) they experienced six different levels of intox-
ication (1=“not intoxicated” to 6=“very stoned”), with scores
ranging from 4 (“not intoxicated” * “every time”) to 24 (“very
stoned” * “every time”). Frequency of acute anxiety reactions was
assessed by asking current cannabis users to report how often they
had felt anxious or panicky when using cannabis (1=“never”
to 5=“every time”), while use to self-medicate for anxiety was
assessed by asking current users how often they had used cannabis
to reduce feelings of anxiety (1=“never” to 5=“every time”). All
of these items specified that respondents answer in relation to their
use/experience of cannabis in the previous 12 months.
History of anxiety was assessed by asking respondents if they
had ever experienced anxiety (1=“never” to 6=“this is always
an issue for me”), with this item used to classify participants
in relation to lifetime anxiety (0=“no,” 1=“yes”). All affected
participants were asked to report the age at which they had first
experienced anxiety. This item, in conjunction with reported age
at first use of cannabis, was used to determine pre-existing anx-
iety (0=“no,” 1=“yes”). Participants were also asked to report
whether there was a history of anxiety and/or depression within
their family (0=“no,” 1=“yes”).
State-anxiety and stress were assessed using the 42-item ver-
sion of the DASS (31). Participants rated the extent to which each
state had been experienced over the past week using a 4-point
scale (0=“did not apply to me at all” to 3=“applied to me very
much or most of the time”). Each of the three subscales, depres-
sion, anxiety, and stress, consists of 14 items and has a maximum
scoring range of 0–42, with higher scores indicating higher levels
of the relevant state. Convergent and discriminant validity of the
DASS is reported to be adequate and internal consistency relia-
bilities for the DASS subscales are high, with subscale Cronbach’s
alphas ranging from 0.90 to 0.95 (41). In this study, Cronbach’s
alphas for the subscales were high, ranging from 0.93 to 0.97. For
the purposes of this study, only results relating to the anxiety and
stress scales are reported.
PROCEDURE
To gain access to the online questionnaire, participants clicked on
the link that was provided to them in the recruitment message.
They were first presented with an information page outlining
the purpose of the study and providing relevant information to
enable informed consent to participate to the study. If consent
was indicated, participants were then directed to the first page of
the questionnaire. It took approximately 20 min for questionnaire
completion. This study was conducted with full human research
ethics committee approval.
STATISTICAL ANALYSES
Due to the large number of hypotheses and overlapping analyses
planned to test them, a summary is provided in Table 1.
A chi-squared analysis was used to test hypothesis 1a, with the
three cannabis use groups (never, past, current) compared in rela-
tion to prevalence of lifetime anxiety (yes, no). Hypotheses 1b,
2a, and 5a were tested with two one-way analysis of variances
(ANOVAs) examining cannabis use group (never, past, current)
differences in state-anxiety and stress. Pearson’s bivariate corre-
lation coefficients were calculated on data from current cannabis
users to identify variables (independent and potential confounds)
for inclusion in the three hierarchical multiple regression analy-
ses that were completed to test hypotheses 2b (dependent variable
[DV]: state-anxiety), 3a/5b (DV: self-medication), and 3b/5b (DV:
frequency of use). A fourth hierarchical multiple regression analy-
sis, with acute anxiety reactions as the dependent variable, was
completed to assist in the development of a path analysis model. All
these statistical analyses were completed using IBM SPSS Statistics
22 Software.
Finally, path analyses were completed to test hypotheses 4
and 5c. Three models were tested: state-anxiety only (Model 1,
depicted in Figure 1), state-anxiety and stress (Model 2, depicted
in Figure 1), and a third model that was informed by the results
from the correlation and hierarchical regression analyses (Model 3,
depicted in Figure 4). Path analyses were performed in IBM SPSS
Amos 22 using the maximum likelihood method of estimation. In
accordance with Hu and Bentler (42), good model fit was assessed
using the combination of chi-squared (χ2 > 0.05), the Tucker–
Lewis index (TLI> 0.95), comparative fit index (CFI> 0.95), and
root mean square error of approximation (RMSEA< 0.05).
RESULTS
DIFFERENCES BETWEEN CANNABIS USE GROUPS
As can be seen in Table 2, participants in the three cannabis use
groups were found to differ in relation to gender and age, with
current users younger on average than past users and the cur-
rent use group containing disproportionately more males than
the other two groups. Lifetime anxiety rates were also found to
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Table 1 | Statistical analyses planned to test each theory and hypothesis.
Theory and hypotheses Planned analyses
1. Common underlying factors
a. Lifetime anxiety: CU=PU>NU Chi-square: cannabis group× lifetime anxiety
b. State-anxiety: CU=PU>NU ANOVA: IV= cannabis group, DV= state-anxiety
2. Anxiety caused by cannabis use
a. State-anxiety CU>PU and NU ANOVA: IV= cannabis group, DV= state-anxiety
b. State-anxiety: exposure/dose-response for CU Regression: IV= cannabis use factors, DV= state-anxiety
3. Self-medication
a. Self-medication predicted by state-anxiety Regression: IV= state-anxiety, DV= self-medication
b. Frequency of use predicted by state-anxiety and self-medication Regression: IV= state-anxiety, self-medication DV= frequency
4. Reciprocal feedback loop
Cannabis use for self-medication of state-anxiety central to reciprocal associations Path analysis: Model 1
5. Stress misattribution
a. Stress: CU>PU>NU ANOVA: IV= cannabis group, DV= stress
b. Stress stronger predictor of self-medication and frequency of use than
state-anxiety
Regression: IV= state-anxiety, stress, DV= self-medication
c. Cannabis use for self-medication of stress central to reciprocal associations Path analysis: Model 2
CU, current users; PU, past users; NU, never used; IV, independent variable; DV, dependent variable.
Table 2 | Means and standard deviations (SD) and cannabis use group differences.
Never used
(NU; N=45)
Past use
(PU; N=102)
Current use
(CU; N=173)
All (N=320) Group differences
Gender (% male)a 33% 40% 64% 52% CU>PU and NU***
Current ageb 32.3 (13.95) 37.1 (10.71) 29.5 (11.19) 32.3 (11.92) CU<PU***
Lifetime anxietya 40% 72% 68% 65% NU<CU and PU**
State-anxietyb 5.7 (9.75) 5.3 (7.26) 5.3 (6.77) 5.3 (7.39) Nil
Stressb 8.6 (10.05) 10.8 (9.19) 8.7 (8.99) 9.4 (9.23) Nil
Depressionb 8.3 (12.06) 8.4 (10.25) 7.5 (9.56) 7.9 (10.15) Nil
Age at anxiety onsetb 20.1 (12.88) 19.6 (8.60) 17.4 (7.62) 18.5 (8.75 Nil
Age cannabis onsetb – 16.9 (3.95) 16.3 (5.07) 16.5 (4.69) Nil
Family history anxietya 50% 66% 53% 57% Nil
Family history depressiona 59% 75% 65% 68% Nil
aChi-squared analyses;
bANOVAs; *p<0.05, **p<0.01, ***p<0.001.
differ between the three user groups. Specifically, 40.0% (n= 18)
of the participants who had never used cannabis reported having
experienced anxiety at some time during their lifetime, which was
significantly lower than the 67.6% (n= 117) of current users and
71.8% (n= 73) of past users who reported lifetime anxiety: χ2(2,
N = 321)= 15.03, p= 0.001. However, no cannabis use group dif-
ferences were found in relation to state-anxiety [F(2,290)= 0.06,
p= 0.944, η2 < 0.001] or stress symptomology: F(2,290)= 1.71,
p= 0.182, η2= 0.012 (see Table 2).
ASSOCIATIONS BETWEEN VARIABLES
The inclusion of independent (IV) and potentially confounding
(CV) variables in the four hierarchical multiple regressions was
guided by the Pearson’s bivariate correlation analyses results for
current cannabis users (see Table 3), with CVs entered at step 1
and IVs entered in subsequent steps in the analyses.
In the first regression analysis, a significant proportion of vari-
ance in state-anxiety was predicted by current age, pre-existing
anxiety,average intoxication,and acute anxiety reactions: R= 0.43,
Adj. R2= 0.16, F(4,126)= 7.02, p< 0.001. However, acute anxiety
reactions (β= 0.27, p= 0.003) were the only significant predic-
tors in the final model (see Table 4). In the second regression
analysis, the use of cannabis for self-medication of anxiety was
significantly predicted by pre-existing anxiety, state-anxiety, and
stress: R= 0.35, Adj. R2= 0.10, F(3,150)= 6.79, p< 0.001. While
state-anxiety was a significant predictor in the second model
of this regression (β= 0.23, p= 0.004), it was no longer sig-
nificant (β= 0.06, p= 0.587) once stress was entered. As such,
stress (β= 0.25, p= 0.021) was the only significant predictor of
self-medication in the final model (see Table 4).
The third regression analysis, investigating frequency of
cannabis use, contained only two variables: acute anxiety reactions
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Table 3 | Correlations between key variables for current cannabis users.
1 2 3 4 5 6 7 8 9 10
State-anxiety –
Stress 0.690*** –
Lifetime anxiety 0.355*** 0.404*** –
Pre-existing anxiety 0.181* 0.116 0.252** –
Acute anxiety reactions 0.355*** 0.329*** 0.257** 0.061 –
Self-medication 0.257** 0.309*** 0.398*** 0.182* −0.082 –
Frequency of use 0.014 0.074 0.135 0.109 −0.179* 0.459*** –
Average intoxication 0.286*** 0.352*** 0.131 0.076 0.355*** −0.022 −0.166* –
Average potency −0.073 0.076 −0.038 −0.027 −0.031 0.106 0.262** 0.134 –
Age at 1st use −0.006 −0.019 <0.001 0.223** −0.151 0.072 −0.021 −0.078 −0.136 –
Current age −0.231** −0.095 −0.127 −0.120 −0.245** 0.033 0.099 −0.320*** 0.060 0.276***
Gender −0.034 0.133 −0.024 0.011 0.102 −0.123 −0.144 −0.024 −0.085 −0.091
*p<0.05; **p<0.01; ***p<0.001.
Table 4 | Summary of hierarchical regression analyses for variables predicting state-anxiety, self-medication, frequency of use, and acute
anxiety reactions.
Model 1 Model 2 Model 3
B SE B β B SE B β B SE B β
State-anxiety R2=0.080; F for ∆R2=5.36** R2=0.125; F for ∆R2=6.45* R2=0.187; F for ∆R2=9.24**
Current age −0.13 0.05 −0.21* −0.09 0.05 −0.15 −0.07 0.05 −0.11
Pre-existing anxiety 2.32 1.22 0.17 2.07 1.19 0.15 2.14 1.16 0.15
Average intoxication 0.65 0.26 0.23* 0.41 0.26 0.14
Acute anxiety reactions 1.78 0.59 0.27**
Self-medication R2=0.038; F for ∆R2=5.85* R2=0.089; F for ∆R2=8.37** R2=0.122; F for ∆R2=5.43*
Pre-existing anxiety 0.53 0.22 0.19* 0.42 0.22 0.15 0.42 0.22 0.15
State-anxiety 0.04 0.15 0.23** 0.01 0.02 0.06
Stress 0.04 0.02 0.25*
Frequency of use R2=0.029; F for ∆R2=4.05* R2=0.221; F for ∆R2=33.52***
Acute anxiety reactions −0.47 0.23 −0.17* −0.37 0.21 −0.13
Self-medication 0.96 0.16 0.44***
Acute anxiety reactions R2=0.058; F for ∆R2=5.74* R2=0.124; F for ∆R2=3.47* R2=0.141; F for ∆R2=0.90
Current age −0.02 0.01 −0.24* −0.01 0.01 −0.17 −0.01 0.01 −0.16
Frequency of use −0.05 0.04 −0.12 −0.06 0.04 −0.15
Average intoxication 0.09 0.05 0.22* 0.07 0.05 0.16
State-anxiety 0.01 0.02 0.06
Stress 0.01 0.02 0.09
*p<0.05; **p<0.01; ***p<0.001.
and use of cannabis for self-medication of anxiety. Together these
variables accounted for 21% of variance in frequency of cannabis
use [R= 0.47, Adj. R2= 0.21, F(2,138)= 19.27, p< 0.001]; how-
ever, only self-medication (β= 0.44, p< 0.001) explained a sig-
nificant proportion of variance in the final model. In the final
regression analyses, the five predictor variables explained 9% of
variance in acute anxiety reactions to cannabis use: R= 0.38, Adj.
R2= 0.09, F(2,148)= 2.29, p= 0.016. Nevertheless, none of the
variables independently explained a significant amount of variance
in the final model (see Table 4).
MODEL TESTING
Path analyses were completed to test three alternate models of
the relationships between anxiety and cannabis use variables. The
first model included state-anxiety but not stress (see Figure 2).
The second model included both state-anxiety and stress (see
Figure 3). The third model also included both state-anxiety
and stress, but differed from the second model in that it was
informed by the correlation and hierarchical multiple regression
findings. As such, pre-existing anxiety was included as a vari-
able and average potency was excluded. Furthermore, the paths
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Frequency of Use
Average Potency
Acute Anxiety
Reac!ons 
Self-Medica!on
Average Intoxica!on
State-Anxiety
R
2 
=.14
.31**
.37***
.23*
.13
.00
.38***
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2 
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R
2 
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2 
=.09
R
2 
=.01
FIGURE 2 | Path analysis of Model 1. With the exception of noted R2
values, all values are standardized regression weights (β), dashed lines
indicate non-significant associations. Model fit: χ2(7)=11.12, p=0.133;
TLI=0.804; CFI=0.909; RMSEA=0.079 (0.000, 0.162). *p<0.05,
**p<0.01, ***p<0.001.
between variables in this third model were guided by suggested
mediation effects indicated within the regression results. That is,
when an IV was significant in one regression model and then
became non-significant after the addition of a second IV, this
suggested that the relationship between the first IV and the DV
in question may be mediated by the second IV. For example,
in the second regression analyses, state-anxiety was a signifi-
cant predictor of self-medication until stress was entered, thus
suggesting that the association between state-anxiety and self-
medication is mediated by stress. This third model is illustrated in
Figure 4.
The fit indices for all three path analysis models are displayed
in Table 5. A non-significant chi-squared result indicates that the
proposed model is consistent with the data; all three path mod-
els met this criterion for good model fit. The TLI typically ranges
from 0 to 1 (values occasionally fall slightly outside this range)
with values greater than 0.95 indicative of a good fit; only Model 3
met this criterion. Similarly, the CFI ranges from 0 to 1 with values
above 0.95 being indicative of good fit; Models 2 and 3 met this
criterion. RMSEA values also range from 0 to 1; however, values
less than 0.05 are considered indicative of good fit; only Model
3 met this criterion. These results indicate that Models 1 and 2
do not fit adequately with the data. In contrast, the fit indices for
Model 3 indicate an excellent fit.
The path analysis results for Model 3 indicate that: (1) pre-
existing anxiety is associated with increased levels of state-anxiety
(β= 0.22, p= 0.026), which is then associated with increased lev-
els of stress symptomology (β= 0.75, p< 0.001), with this in
turn associated with increased frequency of use of cannabis to
self-medicate for anxiety symptoms (β= 0.45, p< 0.001), leading
to increased frequency of cannabis use (β= 0.36, p< 0.001); (2)
state-anxiety is associated with higher average levels of intoxication
(β= 0.34, p< 0.001), which is associated with more frequent acute
anxiety reactions (β= 0.23, p= 0.025). While non-significant,
the positive association between acute anxiety reactions and
state-anxiety (β= 0.16, p= 0.120) and the negative associations
with self-medication (β= -0.18, p= 0.056) and frequency of use
(β= -0.13, p= 0.168) contributed nonetheless to the amount of
variance explained within the model.
DISCUSSION
This study aimed to clarify the nature of the associations evi-
dent between cannabis use and anxiety variables and to explore
the role of stress within these relationships. To do this, key ele-
ments of each of the four theories commonly posited to explain
the relationship between cannabis use and anxiety were tested.
Additionally, a fifth possible explanation for the associations evi-
dent between cannabis use and anxiety was posited, with the
stress-misattribution hypothesis based on the possibility that
stress/tension symptomology could be misconstrued as anxiety,
thus contributing, at least in part, to the high levels of comorbid-
ity reported between anxiety and cannabis use. A large number of
hypotheses were tested, with mixed results. These will be discussed
in turn, and are summarized in Table 6.
The common factors theory suggests that cannabis use and
anxiety are unrelated, with apparent associations simply the by-
product of underlying factor/s that lead to the development of
cannabis use and anxiety independently (16–18). The veracity of
this theory was tested by comparing the prevalence rates of lifetime
anxiety across three cannabis use groups: never used, past use, and
current use. In line with the hypothesis, the prevalence of lifetime
anxiety was significantly lower in the never used group than for
past and current use groups, with the latter two groups having sim-
ilar levels of prevalence. This finding is consistent with reported
differences in comorbidity commonly reported from large epi-
demiological studies for non-and current users [e.g., Ref. (3–5)].
The second hypothesis testing the common factors theory was
also supported, with current and past cannabis users found to be
experiencing similar levels of state-anxiety. The lack of difference
between these groups suggests that current exposure to cannabis
does not increase levels of state-anxiety and vice versa. Together
these findings support the common factor theory by indicating
that the tendency to use cannabis and experience anxiety is highly
comorbid but, with state-anxiety found not to be associated with
current cannabis use, it is suggested that such comorbidity is asso-
ciated with a common underlying factor (e.g., childhood adversity
or maltreatment).
It is important to note, however, that to be consistent with the
core argument of this theory, individuals who have never used
cannabis should report lower levels of state-anxiety on average
than both current and past cannabis users. This was not found
in the present study. Further to this, if comorbidity between life-
time anxiety and cannabis use is due to common factors occurring
during childhood/adolescence that are disproportionately experi-
enced by cannabis users (past and current) in comparison to never
users, then we would also expect to see the onset of any anxiety
occurring at an earlier age for individuals who had used cannabis
than for individuals who had not. This was also not evident for
the present sample. As such, the common factors theory is par-
tially supported by these results, yet it seems that the assumed distal
events/circumstances responsible for independently increasing the
incidence of lifetime anxiety and cannabis use for some individuals
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Frequency of Use
Average Potency
Acute Anxiety
Reac!ons 
Self-Medica!on
Average Intoxica!on
State-Anxiety
R2 =.14
.12
.29*
.23*
.14
.00
.35***
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-.05
Stress
.39**
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.01
R2 =.17
R2 =.01
R2 =.01
R2=.14
R2 =.10
FIGURE 3 | Path analysis of Model 2. With the exception of noted R2 values, all values are standardized regression weights (β), dashed lines indicate
non-significant associations. Model fit: χ2(9)=13.23, p=0.152; TLI=0.924; CFI=0.967; RMSEA= 0.070 (0.000, 0.146). *p<0.05, **p<0.01, ***p<0.001.
Frequency of Use
Acute Anxiety
Reac!ons
Self-Medica!on
Average Intoxica!on
Pre-exis!ng Anxiety
R
2 
=.16
.22*
.34***
.23*
.36***
-.13
.16
StressState-Anxiety
.75*** .45***
-.18
R
2 
=.20R
2 
=.56R
2 
=.10
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2 
=.14
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=.08
FIGURE 4 | Path analysis of Model 3. With the exception of noted R2 values, all values are standardized regression weights (β), dashed lines indicate
non-significant associations. Model fit: χ2(12)=9.96, p=0.620; TLI=1.027; CFI=1.000; RMSEA= 0.000 (0.000, 0.089). *p<0.05, **p<0.01, ***p<0.001.
Table 5 | Fit indices for the path analysis models.
Model 1 Model 2 Model 3
State-anxiety State-anxiety and stress State-anxiety and stress
with mediation
χ2 χ2(7)=11.12, p=0.133 χ2(9)=13.23, p=0.152 χ2(12)=9.96, p=0.620
TLI 0.804 0.924 1.027
CFI 0.909 0.967 1.000
RMSEA 0.079 (0.000, 0.162) 0.070 (0.000, 0.146) 0.000 (0.000, 0.089)
may not result in ongoing repercussions that lead to subsequent
increased levels of state-anxiety.
Similarly, reported stress symptomology did not differ signifi-
cantly between the three cannabis use groups. These findings may
suggest that the current cannabis users in the present study were
no more afflicted by proximal or distal stressors than past users or
those who had never used cannabis, which would be inconsistent
with past research [e.g., Ref. (10, 14, 20, 30, 33, 34)]. However,
as the participants were not specifically asked about life stressors
(current or past), as per van der Pol et al. (30), we cannot rule out
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Table 6 | Summary of findings in relation to each theory and hypothesis.
Theory and Hypotheses Outcome
1. Common underlying factors
a. Lifetime anxiety: CU=PU>NU Supported
b. State-anxiety: CU=PU>NU Partial: CU=PU=NU
2. Direct causation
a. State-anxiety CU>PU and NU Rejected: CU=PU=NU
b. State-anxiety: exposure/dose-response for CU Partial: only intoxication, but became non-significant when
acute anxiety reactions added as IV
3. Self-medication
a. Self-medication predicted by state-anxiety Partial: became non-significant when stress added as IV
b. Frequency of use predicted by state-anxiety and self-medication Partial: predicted by self-medication, not state-anxiety (or
stress)
4. Reciprocal feedback loop
Cannabis use for self-medication of state-anxiety central to reciprocal associations Rejected: Model 1 met only one of the four fit criteria
5. Stress misattribution
a. Stress: CU>PU>NU Rejected: CU=PU=NU
b. Stress stronger predictor of self-medication and frequency of use than state-anxiety Partial: for self-medication but not frequency of use
c. Cannabis use for self-medication of stress central to reciprocal associations Rejected: Model 2 met two of the four fit criteria
d. Adjusted model, informed by correlation and regression findings Supported: Model 3 met all four fit criteria
CU, current users; PU, past users; NU, never used; IV, independent variable; DV, dependent variable.
the possibility that there were unassessed group differences, such
that past users and those who had never used cannabis may have
been exposed to a similar or greater number stressors than the
current cannabis users. Nevertheless, this finding is not consistent
with the stress-misattribution hypothesis put forward in this paper.
The direct causation theory proposes that the association
between cannabis use and anxiety is causal, with cannabis use
causing anxiety in otherwise unaffected individuals (16, 18). For
this theory to hold, we would expect to see an exposure/dose rela-
tionship between cannabis use and anxiety. Two hypotheses were
proposed to test this. As noted above, the first of these, that cur-
rent cannabis users would report higher levels of state-anxiety than
both past and never used groups, was not upheld for the present
sample. This finding suggests that current exposure to cannabis use
is not associated with increased state-anxiety. Similarly, the lack of
group differences discussed above in relation to stress symptomol-
ogy suggests that current exposure to cannabis is not associated
with increased stress/tension.
The second hypothesis involved investigating cannabis dose-
related variables (i.e., frequency, potency, and intoxication) and
acute anxiety reactions as predictors of state-anxiety. Interest-
ingly, bivariate analyses indicated that neither frequency of use or
average potency was significantly related to state-anxiety. Intoxi-
cation was found to account for a significant amount of variance
in state-anxiety, after controlling for current age and pre-existing
anxiety, in the regression analyses. However, this association was
no longer significant after acute anxiety reactions was entered into
the analysis, with this variable being the only significant predictor
of state-anxiety in the final regression model. Given the moderately
strong bivariate association indicated between level of intoxication
and acute anxiety reactions, and the known links between them
[e.g., Ref. (6, 43)], this result is not altogether surprising. Nev-
ertheless, these findings suggest that there is not a direct causal
relationship between cannabis use and state-anxiety but, rather,
that higher levels of intoxication can induce acute anxiety reac-
tions, which may then lead to increased levels of state-anxiety for
some users – acute anxiety reactions are estimated to occur in
20–30% of users (6).
The self-medication hypothesis posits that the association
between cannabis use and anxiety is due to anxious individu-
als using cannabis to relieve their anxiety symptoms (16, 18, 21).
If this is the case, then state-anxiety should be positively associ-
ated with, and predictive of, the frequency with which cannabis is
used specifically to relieve symptoms of anxiety. This hypothesis
was partially upheld, with state-anxiety accounting for a signif-
icant proportion of variance in self-medication after controlling
for pre-existing anxiety. However, once stress was entered into the
regression analysis, state-anxiety was no longer significant. While
this finding is evidently related to the large overlap in variance
between state-anxiety and stress (R2= 0.56), it is also sugges-
tive of a mediation effect, whereby the effects of state-anxiety
on self-medication are mediated by the effects of stress – self-
medication was more strongly associated with stress (r= 0.31)
than state-anxiety (r= 0.26) in the bivariate analyses.
The second hypothesis proposed to test the self-medication
hypothesis, that frequency of cannabis use would be predicted
by state-anxiety and use for self-medication, was also partially
upheld. As noted above, state-anxiety was not associated with fre-
quency of use; however, there was a strong positive association
indicated between self-medication and frequency of use. Putting
these findings together, it appears that any impact of state-anxiety
(or stress) on frequency of use comes by way of self-medication.
That is, individuals experiencing state-anxiety and/or stress who
use cannabis to relieve their symptomology tend to use cannabis
more frequently than unaffected/less affected individuals, and it is
the stated use of cannabis for such self-medication purposes that
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seem to drive frequency of use rather than actual levels of symp-
tomology. Hence, there is some support here for the veracity of
the self-medication hypothesis, but it appears that an individual’s
belief that they are using cannabis to relieve anxiety symptoms is
more indicative of their frequency of use than the actual severity
of the symptomology for which they are self-medicating. Addi-
tionally, they are more likely to be self-medicating symptoms of
stress than of state-anxiety.
Evidently, these associations between anxiety, stress, and self-
medication provide support for the stress-misattribution hypothesis
posited in the current paper, being consistent with the idea that
cannabis users may be misattributing symptoms of stress/tension
to anxiety. That is, affected individuals may believe that they are
using cannabis to relieve symptoms of anxiety, and thus report
use for the self-medication of this disorder, while, in fact, what
they are experiencing are symptoms of stress (e.g., tension, persis-
tent arousal symptoms, irritability, and difficulty relaxing) as well
as, or instead of, symptoms of anxiety [e.g., arousal/tension and
fear-related symptoms and cognitions; (31)]. It should be noted,
however, that stress was not found to be associated with frequency
of cannabis use. Thus, even though cannabis users may misiden-
tify the condition for which they are self-medicating, experiencing
more severe stress/tension symptomology was not found to be
directly associated with increased frequency of cannabis use.
Path analyses were used to test the reciprocal feedback loop
hypothesis, which posits that cannabis use and anxiety result from
common factors but then act to exacerbate each other through
direct causality and/or self-medication (16). Two models were
tested, one with (Model 1) and one without (Model 2) stress
included as a variable. In Model 1, two significant paths were
indicated: (i) from state-anxiety to average intoxication to acute
anxiety reactions and (ii) from state-anxiety to self-medication to
frequency of use. However, paths from state-anxiety and average
potency to acute anxiety reactions and from frequency of use to
state-anxiety were not significant. Furthermore, this model only
met one of the four fit criteria. Model 2 was a better fit with
the data, meeting two of the criteria, suggesting that the addi-
tion of stress to the model was an improvement. While the path
from state-anxiety to average intoxication to acute anxiety reac-
tions remained significant in this second model, the association
between state-anxiety and self-medication in the second path was
no longer significant. Rather, the significant path ran from stress to
self-medication to frequency of use. Nevertheless, the majority of
associations between variables proposed in this variable was non-
significant, and the model was not deemed to be a good fit for the
data. Therefore, a third model was developed, with the correlation
and hierarchical regression results used for guidance.
In Model 3, the pathway from state-anxiety to average intox-
ication to acute anxiety reactions remained significant, but was
lengthened with the addition of a positive association from pre-
existing anxiety to state-anxiety. The second pathway was also
modified, now running from pre-existing anxiety to state-anxiety
to stress to self-medication to frequency of use. Pathways from
acute anxiety reactions to state-anxiety (positive), self-medication
(negative), and frequency of use (negative) were not found to be
significant. Thus, Model 3 suggests that pre-existing anxiety (i.e.,
onset of anxiety prior to any cannabis use) is associated with higher
levels of state-anxiety, which is then associated with higher levels
of stress symptomology, leading individuals to self-medicate with
cannabis and use cannabis more frequently. Additionally, it is sug-
gested that higher levels of state-anxiety are associated with higher
average levels of intoxication, which increases the frequency with
which acute anxiety reactions are experienced. This model was
found to be an excellent fit with the data, exceeding suggested
cutoffs for all four fit indices (42).
This model provides some support the self-medication hypoth-
esis, on the proviso that self-medication is primarily for stress
symptomology, but does not support the direct causation the-
ory. If pre-existing anxiety is considered a possible indicator of
adverse events/circumstances in childhood/early adolescence, the
model could be deemed to be somewhat consistent with the com-
mon factors theory. However, as this model does not include any
variable that is representative of early cannabis use (age at onset
of cannabis use was not significantly associated with any other
cannabis variables, state-anxiety, self-medication, acute anxiety
responses, or stress), the analysis cannot reasonably be consid-
ered to assess the common factors theory in any meaningful way.
Nevertheless, Model 3 is somewhat consistent with the reciprocal
feedback loop theory, indicating that state-anxiety, and through
its pre-existing anxiety, plays a role in the escalation of cannabis
use via stress and self-medication, while also playing a role in
the exacerbation of acute anxiety reactions via increased average
levels of intoxication. It is important to note that, in the model,
neither frequency of use nor average intoxication was found to
be predictive of state-anxiety, stress, or self-medication and asso-
ciations between acute anxiety reactions and state-anxiety and
self-medication were not significant. Hence, these findings are not
in keeping with the theory’s central argument that cannabis use
exacerbates state-anxiety.
The model does support the stress-misattribution hypothesis,
suggesting that participants reporting self-medication of anxiety
were likely to be treating stress symptomology instead of, or as
well as, anxiety symptomology. Such an interpretation is consis-
tent with prior study results indicating that the most common
reason for cannabis use is to relieve stress/tension and anxiety
[e.g., Ref. (8, 22)]. Further to this, Model 3 is consistent with the
posited mood amplification effects of cannabis, which suggests
that people with underlying anxieties may be especially vulnerable
to experience acute adverse drug effects (43). The model is also
concordant with study results indicating that anxiety may occur
during or after cannabis intoxication (27, 44). Additionally, the
results are consistent with Van Dam et al.’s (29) finding that clin-
ically anxious heavy drug users exhibited greater drug use than
non-anxious heavy drug users.
A number of limitations may, however, have lessened the verac-
ity of the study results. First, an online survey methodology was
used to capture self-reported anxiety symptoms from a general
population, rather than clinical, sample, thus limiting the general-
izability of the findings. Further to this, clinical anxiety diagnosis
details were not collected or verified. Second, while current users
were asked to report the potency of the cannabis they typically con-
sumed, there was no opportunity for them to report the actually
effects of use (beyond intoxication) to reflect known differences in
effects associated with different cannabis species/breeds/hybrids
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or growing techniques (e.g., high vs low THC and CBD content,
hydroponic vs naturally grown, etc.). Further to this, it is possible
that the variations in potency encountered by cannabis users could
increase the likelihood of anxiety-related experiences of use, such
as when there is a higher than expected level of THC, which is not
accounted for by the users (i.e., through titration of dose). Third,
it is possible that some participants may have mixed tobacco with
their cannabis or used other substances concurrently, potentially
confounding the observed findings. Fourth, while the path mod-
els appear to suggest causal pathways between the variables, the
fact that the data were cross-sectional means that causal infer-
ences cannot be drawn. Furthermore, as there is a large range of
variables that have been found in past studies to be associated in
some way with cannabis use and/or anxiety that were not assessed
in this study, it is possible that important factors may have been
overlooked.
Nevertheless, the results of this study have important implica-
tions for the prevention and treatment of anxiety/stress disorders
in cannabis users. These may also be of some benefit in relation
to cannabis use-related panic attacks, which could be similarly
related to stress misattribution. First, while cannabis users often
report using the drug to relieve anxiety, they may actually be self-
medicating symptoms of stress, the symptoms of which are readily
treated by a range of well-accepted stress-reduction techniques.
For example, highly stressed cannabis users could be provided
with alternate stress-reduction techniques (i.e., relaxation training,
physical exercise, mindfulness exercises) to reduce their symptoms
of stress/anxiety and prevent the escalation in cannabis use that
appears to be associated with its use for self-medication purposes.
Second, cannabis users with pre-existing or current anxiety may
be particularly vulnerable to experience the anxiogenic effects of
cannabis, especially if they get highly intoxicated when the con-
sume cannabis. Such individuals could be advised to restrict ses-
sional intake/dose to reduce the likelihood of experiencing acute
cannabis-related anxiety reactions. Furthermore, as two different
anxiety-related paths were indicated, though both including the
link from pre-existing anxiety to state-anxiety, treatments could be
tailored to reflect that individuals vulnerable to experiencing acute
anxiety reactions to cannabis use do not appear to be the same
individuals who are using cannabis for self-medication purposes.
In summary, the findings provided some support for all of
the theories, with the exception of the direct causation theory.
However, none of the theories was fully supported. The common
factors theory was supported by the finding that participants who
had never used cannabis were less likely to report lifetime anxiety
than either past or current cannabis users, but was not consistent
with the finding that the three groups did not differ in relation
to age at onset of anxiety, or their levels of state-anxiety or stress.
The self-medication theory holds only if it is broadened to account
for the treatment of stress symptoms and also acknowledges that
cannabis users’ belief that they are self-medicating anxiety is a
stronger predictor of frequency of use than the actual severity of
the anxiety symptomology they report they are relieving. The rec-
iprocal feedback loop theory was only partially supported by the
link from state-anxiety to intoxication to acute anxiety responses.
However, with frequency of use not being predictive of state-
anxiety, there was no clear feedback loop to support the premise
that cannabis use exacerbates state-anxiety. These results suggest
that the relationship between cannabis use and anxiety is complex
and likely to be obscured, at least in part, by the misidentifica-
tion of overlapping symptoms of stress and anxiety. As such, the
posited stress-misattribution hypothesis was partially supported.
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